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Radiofrequency Thermal Ablation of
Hepatocellular Carcinomas
epatocellular carcinoma (HCC) is one of the most common malignant
neoplasms occurring worldwide (1), and in patients with this condition,
surgical excision has evolved as a treatment option. Surgical resection
currently provides the best chance of long-term tumor-free survival, but the survival
rates following liver resection are low and only a minority of patients are eligible for
the surgical procedure (2 4). Liver dysfunction in patients with hepatic cirrhosis
makes surgical resection risky, and several minimally invasive techniques for the local
control of HCC have therefore been developed. These fall into one of two categories:
the direct intratumoral injection of compounds such as absolute ethanol (5) and hot
saline (6), and thermal ablation techniques such as interstitial laser photocoagulation
(7), microwave ablation (8), and radiofrequency (RF) ablation (9). Among these, the
clinical efficacy of percutaneous ethanol injection (PEI) has been established and the
procedure is considered an acceptable alternative to surgery for the treatment of HCC
(5). Most of the remaining techniques are at the experimental stage, and the experi-
ence obtained to date is thus preliminary.
RF thermal ablation is a local ablation technique designed to destroy the tumor by
heating. Numerous experimental and clinical studies have concluded that in patients
with unresectable liver tumors, the technique is safe and effective (10 20). The con-
cept of using heat to treat tumors is very old, and was used as far back as Greek and
Roman times (21), when cautery was used to treat superficial tumors. Heat therapy is
based on the observation by Coley (22) that tumor cells are more sensitive to heat
than are normal cells. The use of RF to induce controlled thermal injury in living tissue
is a well-established technique used by neurosurgeons since the mid-1960s (23), and in
the early 1980s LeVeen et al. found that external radiofrequency was effective in
treating tumors located deep in the body (24). McGahan et al. (9) pioneered the appli-
cation of RF ablation to the treatment of malignant hepatic tumors. With the develop-
ment of high-resolution cross-sectional imaging modalities and interventional tech-
niques, the percutaneous placement of a heating device powered with energy from a
microwave (25) or radiofrequency generator has become possible. Unfortunately, the
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Although surgical resection remains the best option as potentially curative ther-
apy for hepatocellular carcinoma, radiofrequency thermal ablation has begun to
receive much attention as an effective minimally invasive technique for the local
control of unresectable malignant hepatic tumors. Most recent radiofrequency
devices equipped with a powerful generator and larger needle electrode permit
larger thermal lesions, up to 5 cm in diameter, with a single ablation. In this article,
the author reviews the technical developments and early clinical results obtained
with radiofrequency ablation techniques.
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Radiofrequency (RF) ablationlesions made with initial needle electrodes were no more
than 1.6 cm in diameter, but many investigators have sub-
sequently attempted to solve the size limitation using ap-
proaches which include the use of multiprobe arrays (10)
and saline injection prior to RF ablation (11). These permit-
ted certain advances in the treatment of larger lesions, but
were not a satisfactory response to the problem of large
hepatic tumors. With the introduction of monopolar needle
electrodes with expandable multiple spring wires and a
straight tip needle electrode internally cooled with chilled
saline (12 14), the induction of consistent and predictable
large thermal lesions has become possible. Most recent ex-
pandable needle electrodes permit larger thermal lesions,
up to 5 cm in diameter, with a single ablation. This review
article describes the current status of RF thermal ablation
in HCC, with an emphasis on techniques.
Tissue Response to Heat, and the Principle of 
RF Ablation
Thermal injury to living tissue is known to begin at 42 .
Lethal exposure times at this temperature range from 3 to
50 hours, depending on the tissue involved (26). At tem-
peratures over 43 , lethal exposure times decrease expo-
nentially; at 46 , 8 minutes exposure is enough to cause
cell death. At temperatures over 60 , denaturing of tissue
collagen begins and cell death is inevitable (27, 28), and for
treatment in cases where injury to normal tissue is not a
concern, temperatures of this magnitude are therefore de-
sirable. In clinical practice the tissues around the tip of a
needle electrode are heated to 100 , the temperature re-
quired to induce the desirable degree of injury. It is known,
however, that rapid heating to too high a temperature
(over 100 ) dramatically increases tissue impedance, and
the deposition of RF energy, heat diffusion , and further
coagulation necrosis are limited (29).
Using either ultrasound or CT guidance, an RF needle
electrode is percutaneously introduced directly into a tu-
mor. When the electrode is connected to a generator pro-
ducing alternating electric current, RF is emitted from its
tip, and current within the RF range (460 kHz) passes into
surrounding tissue. The current agitates ions of tumor tis-
sue around the needle electrode, and the frictional heat
produced by ionic agitation induces cellular death via coag-
ulation necrosis. By changing the intensity and duration of
the alternating current, and the size of the electrode, the
size of the thermal lesion can be controlled. 
Indications and Contraindications
We currently limit the use of RF ablation to patients who
are not considered for surgery, or who decline this option.
As yet, there is no consensus as to indication, but investiga-
tors generally recommend that HCCs smaller than 5 cm in
diameter and fewer than four in number are ideal for RF
ablation. We are able to treat lesions larger than this by
making multiple overlapping ablations with recently devel-
oped needle electrodes and powerful generators, but it is
known that the larger the tumor, the greater the incidence
of incomplete treatment.
Because RF ablation can cause bleeding, uncorrectable
coagulopathy due to severe liver dysfunction is an absolute
contraindication. The prothrombin time ratio must be
greater than 50% and the platelet count greater than
70,000/mm
3. Patients with large amounts of ascites, ob-
structive jaudice, evidence of extrahepatic tumors, or ex-
tensive portal venous thrombosis are not suitable candi-
dates for the procedure. A life expectancy of less than 3
months is also a contraindication.
Equipment
At the moment three RF devices, all of which consist of
RF generators, needle electrodes and dispersive ground
pads, are commercially available. The basic principles of
each are similar, but the operational techniques are differ-
ent. Generator power varies between 50 and 200 watts;
some are equipped with functions that display output, tis-
sue impedance, and temperatures in the tissue around the
tip of a needle electrode. In each device, the design of
these electrodes is different (Fig. 1). The first device to be
introduced in Korea, in April 1999, was the RITA  500
model (RITA Medical Systems, Mountain View, Cal.,
Lim
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Fig. 1. Radiofrequency needle electrodes of varying design man-
ufactured by three different companies.
The first three needle electrodes, 15-gauge in external diameter
and insulated except for 0.6 1 cm of their tip, have 4, 9, or 10 re-
tractable hook-like prongs which serve as active electrodes dur-
ing RF ablation. The fourth and fifth have a single 17-gauge
straight-tip and triple-cluster electrodes, internally cooled with
chilled saline solution during ablation. The needles have active
exposed tips 2 4 cm in length.U.S.A.). This consists of a 50-watt electric generator and a
15-gauge needle electrode, insulated except for 0.6 1c m
of its tip. Its hub is a plunger that advances 4 or 7 prongs
from the tip, and when fully deployed, these and the nee-
dle electrode resemble an open umbrella 3 cm in diameter.
All the prongs and uninsulated tip of the needle are active
electrodes, and each curved prong contains a thermocou-
ple at its tip that registers the temperature of surrounding
tissue. With the use of recently developed software, the
temperature around a needle electrode, power, and imped-
ance can be continuously monitored. The more recent
1500 model, manufactured by the same company, is
equipped with a more powerful generator (150 watts) and
a larger needle electrode, 5 cm in diameter, which can in-
duce thermal lesions of up to this size with a single abla-
tion.
The second device ( RF 2000 system) manufactured by
RadioTherapeutics Corporation (Mountain View, Cal.,) in-
corporates a 100-watt generator, a LeVeen 15-gauge,
monopolar array needle electrode, and needle electrodes
2, 3, and 3.5 cm in diameter, the largest of which is able to
induce lesions with a diameter of up to 4 cm. The 15-gauge
electrode consists of a 12- to 15-cm-long insulated cannula
that advances ten individual hook-like arms which are de-
ployed after the needle has been introduced into the tumor.
The third device, manufactured by Radionics
Corporation (Burlington, Mass., U.S.A.), includes a needle
electrode whose tip is internally cooled with chilled saline,
a process thought to increase the size of the thermal lesion.
The device is equipped with a 200-watt generator and uses
either a single 17-gauge straight electrode or clustered elec-
trodes designed in a triangular shape. With the device,
thermal lesions of up to 5 cm in diameter can be induced.
Procedure and Technique
RF ablation can be performed percutaneously, laparo-
scopically, or during laparotomy, and involves conscious
sedation or general anesthesia. For the former, we prefer
the intramuscular injection of 50 mg pethidine hydrochlo-
ride (Pethidine; Samsung Pharmaceutical, Seoul, Korea)
10 20 minutes before the procedure. Whenever patients
report intolerable pain during ablation, an additional 50
mg of the same drug is administered intravenously, with
continuous monitoring of the cardiovascular and respirato-
ry systems. 
Although lesions can be reliably localized using CT, this
part of the procedure has depended mostly on sonography.
For grounding, one or two large dispersive pads are at-
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Fig. 2. HCC located in the mid-zone of the liver surrounded by normal hepatic tissue in a 62-year-old man.
A. Transverse helical CT scan obtained during the hepatic arterial phase prior to RF ablation shows a 2.5-cm HCC (arrow), with ho-
mogenous contrast enhancement in liver segment 5.
B. Transverse helical CT scan obtained one month after RF ablation depicts a round ablated area of low attenuation (arrows), represent-
ing complete necrosis of the tumor. Note that the ablated area covers the entire tumor and the cuff of surrounding normal hepatic tissue.
ABtached to the patient s thigh or back, and after skin cleans-
ing using a sterile technique, local anesthetic (Lidocaine;
Kwang Myung Pharmaceutical, Seoul, Korea) is injected
along the expected needle pathway and a small skin nick is
made. The electrode is passed through the nick and ad-
vanced into the desired portion of the tumor, using real-
time sonographic guidance. Once the needle tip is appro-
priately positioned in the tumor, the electrode prongs are
deployed and ablation is begun. If a RITA device is used,
initial ablation involves partial deployment of the curved
electrodes, but once the temperature at the tip of these
reaches the desired level (usually over 95 ), they are fully
deployed. The temperature is then maintained at 95 100
for ten minutes until the entire tumor or the desired
portion is ablated. After each ablation, the prongs are re-
tracted and the needle is repositioned. At this point, the
needle tract is cauterized and the needle withdrawn from
the liver. With an RTC device, the power used for initial
ablation after deployment of the multiple arrays is 50
watts. At 1, 2, 3, and 4 minutes, 10-watt increments are
applied, to a maximum of 90 watts, until the  roll-off phe-
nomena is observed (i.e., power output falls precipitously
as tissue impedance increases markedly). After a 30-second
pause, ablation is restarted, at 75% of the maximum pow-
er achieved, until  roll-off again occurs. Each tumor or
area of a large tumor is ablated by the application of RF
power during these two phases, and at completion the nee-
dle is removed with the multiple arrays retracted. With a
Radionics device either a single electrode with 2 or 3 cm of
exposed metallic tip or a triple- cluster electrode, depend-
ing on the size and location of the tumor, can be em-
ployed. After the needle electrode is introduced into the
tumor, RF is usually applied for 12 minutes. To maintain a
temperature of 20 25 in the tissue around the needle
tip, a peristaltic pump is used to infuse 0 normal saline
solution into the lumen of the electrodes. During ablation,
generator output , tissue impedance and temperature
around the needle tip are continuously monitored.
For RF ablation to be successful and complete, all malig-
nant tissue must be ablated. The ideal goal is to ablate a
peripheral margin of 0.5 1 cm of normal hepatic tissue
surrounding the tumor, as well as the entire tumor itself:
without adequate safety margins, untreated viable tumor
may remain, leading to treatment failure and local recur-
rence. In general, a single ablation, or two, may be ade-
quate for tumors less than 3 cm in diameter when a needle
electrode at least 3 cm in diameter is used. For larger tu-
mors, however, multiple overlapping ablations should be
performed, according to tumor size. With a needle elec-
trode 3 cm in diameter, a single ablation is applied for tu-
mors < 2 cm in diameter, at least two ablations for those
which are 2~3 cm, and multiple overlapping ablations for
those > 3 cm. For tumors located in the mid-zone of the
liver rather than its periphery or central zone, this treat-
ment strategy may be adopted without difficulty (Fig. 2).
In addition to size, tumor location is one of the important
factors influencing the likely therapeutic outcome. If the
tumor lies in the subcapsular area, no safety margin along
Lim
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Fig. 3. HCC in a 45-year-old man. 
A. Longitudinal US scan of left hepatic lobe shows a 2.8-cm low echogenic HCC (arrows) which is fusiform in shape. The mass abuts on
both liver capsules. Note the 3-cm active tip (arrowheads) of the straight cooled-tip electrode, which conforms to the shape of the mass.
A single ablation lasted for 12 minutes.
B. Portal-phase CT scan obtained 30 minutes after RF ablation reveals the presence of an oval low-attenuating lesion (arrows), with ab-
sence of contrast enhancement within the ablated area. This indicates complete necrosis. 
ABthe capsule is possible. In subcapsular tumors, a safety mar-
gin of normal hepatic tissue is difficult to obtain, but if the
liver capsule overlying the tumor appears to be involved
by the tumor, the capsule should be ablated. Subcapsular
tumors can be effectively treated using either an expand-
able needle electrode with multiple array or a straight
cooled-tip electrode. If a tumor is small and round, the use
of an expandable needle electrode is preferred because the
lesions it induces tend to be more spherical in shape than
those induced by one with a straight tip. For ablating
fusiform tumors, a straight-tip needle electrode is better
because it frequently makes elliptical lesions. Tumors locat-
ed between the anterior and posterior liver capsules (e.g. in
the inferior angle of the right lobe or the lateral segment of
the left ) are often difficult to ablate completely, especially
when they abut on both capsules, and in this particular sit-
uation, the choice of needle electrode is important. When
an expandable electrode is used in narrow spaces, multiple
overlapping ablations involving partial deployment of the
hook-like electrodes are unavoidable even if the tumors
are small: the full deployment of hooks can penetrate the
liver capsule, and this may cause bleeding or unnecessary
thermal injury to adjacent organs. Because its use involves
no risk of penetrating either capsule, and the entire length
of active electrode can be employed, the situation requires
a straight cooled-tip electrode. Additionally, the number of
ablations and  thus  the procedure time are thereby re-
duced (Fig. 3). If the ultrasound-guided percutaneous ap-
proach is used, subcapsular tumors exhibiting exophytic
growth can also be difficult to ablate completely. The best
way to achieve effective necrosis of an exophytic tumor is
to ablate the deepest portion first, thus blocking the blood
supply to the exophytic portion, which is subsequently ab-
lated (Fig. 4). 
Another difficult situation arises when tumors are pre-
sent in the central zone of the liver, near the hepatic hilum.
A tumor in this location is almost always surrounded by
large vessels, and the resultant tissue cooling may make it
difficult to ablate its periphery and the cuff of normal he-
patic tissue. In this situation, the extent of coagulation
necrosis is less than usual, and follow-up CT reveals the
presence of residual perivascular tumor (Fig. 5). On the ba-
sis of experimental and clinical studies (30 32), several in-
vestigators have found that temporary reduction of vascu-
lar flow to the liver during RF ablation by mechanical oc-
clusion of the portal vein and/or arterial vessels, or phar-
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Fig. 4. HCC in a 57-year-old man. 
A. Hepatic arterial-phase CT scan depicts a 4-cm HCC (arrows) in the subcapsular area of the right hepatic lobe, which shows an out-
ward bulge. Using a 3-cm expandable needle electrode, four ablations were performed. The deep portion of the mass was treated first,
and then the exophytic portion.
B. Portal-phase CT scan obtained 13 months after RF ablation shows an ablated lesion (arrows) with no contrast enhancement, indicat-
ing complete necrosis. 
ABmacologic modulation, increased the extent of coagulation
necrosis. When RF ablation is performed percutaneously,
the use of a balloon for mechanical occlusion of the portal
vein is impractical because it is invasive and time consum-
ing. During intraoperative RF ablation after laparotomy,
reduction of vascular inflow by clamping the hepatic artery
and portal vein at the level of the porta hepatis (Pringle
maneuver) is very helpful in increasing the extent of coag-
ulation necrosis. Pharmacologic modulation of hepatic
blood flow has been under investigation and could be the
ideal way of creating more extensive coagulation necrosis
during percutaneous RF ablation. It is, however, not yet
available in clinical practice. We are able to suggest a num-
ber of ways in which the use of current RF devices for the
ablation of tumors surrounded by large vessels may be effi-
cacious. The space between large vessels is usually small
and narrow, and safe ultrasound-guided targeting may thus
be difficult. It is important not to penetrate large vessels
with a needle electrode, since bleeding or pseudoaneurysm
may occur. When RF ablation involves the use of an ex-
pandable needle electrode and its hooks within the lumen
of the vessel are ineffective, the hooks of the multiple ar-
ray should not be placed beyond the vascular wall. To in-
duce satisfactory coagulation necrosis in this situation, mul-
tiple overlapping ablations with partial deployment of the
multiple array are recommended, rather than a single abla-
tion with the needle electrode fully deployed. Even if the
tumor is less than 3 cm in diameter, the recommendation
applies. To avoid penetration of the vessel wall during de-
ployment of the needle electrode, careful monitoring with
real-time ultrasound is essential. If the temperature around
any tip of the multiple array fails to rise, this indicates that
the tip is inside the blood vessel and should be retracted.
For ablation of a tumor surrounded by large vessels, a
straight-tip internally cooled needle electrode may have
advantages over the expandable needle variety. First, be-
cause only the straight part of the active electrode is in-
volved, penetration of the vessel wall is not a matter of
concern. Second, the reduced impedance of the tissues
nearest the needle electrode, induced by internal cooling
with chilled saline, enables heat to diffuse more easily. This,
in turn, allows greater RF energy deposition and can lead
to more extensive coagulation necrosis than is possible
when an expandable needle electrode is used. For ablation
of a tumor surrounded by large vessels, it is also useful to
increase the duration of RF application, regardless of the
type of needle electrode employed; one more ablation
with the needle tip placed in the same position may help
decrease the amount of residual perivascular tumor. This
possible outcome is, however, based on our own experi-
ence and is somewhat speculative; firmer conclusions
should be based on the findings of further studies. 
The ablation procedure almost always creates numerous
microbubbles in heated tissue, and these increase the
echogenicity of the ablated lesion (Fig. 6), a condition
which is known to persist for between 15 minutes and 6
hours (33, 34). Hyperechogenicity may be helpful for mon-
itoring the approximate size of an ablated lesion, but
makes further placement of the needle electrode difficult.
For large tumors, the accurate mapping of multiple over-
lapping ablations is therefore imperative. One good way of
Lim
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Fig. 5. Hepatic arterial-phase CT scan obtained 1 month after RF
ablation of a 4-cm HCC surrounded by large branches of the he-
patic artery and portal vein shows a low attenuating ablated le-
sion (arrows) near the hepatic hilum. Although the tumor has be-
come mostly necrotic, thin enhancing viable tumor (arrowheads)
remains along the posterior branch of the right hepatic artery.
Fig. 6. Oblique US scan of the liver obtained during RF ablation
shows an echogenic ablated lesion (arrows), the result of numer-
ous microbubbles produced by thermal ablation.treating a large tumor is to deal with the deepest portion
first; in this way increased echogenicity does not obscure
its untreated portions.
Evaluation of Therapeutic Effect
No data concerning the accuracy of CT in depicting
residual tumors after RF ablation have been published, and
as a standard of reference, the dynamic helical mode suf-
fers certain limitations. Nonetheless, CT has been widely
used in the evaluation of therapeutic response after RF ab-
lation. Complete tumor necrosis (successful treatment) is
considered to have occurred when follow-up CT reveals no
foci of enhancement within the ablated lesion or at its pe-
riphery (Figs. 2, 4). Any focal enhancement within the tu-
mor or increase in size of the ablated tumor should be con-
sidered indicative of residual or recurrent lesion (Fig. 7).
We treat residual or recurrent tumor with additional RF
ablation, using three-phase helical CT to evaluate thera-
peutic outcome; because reactive hyperemia in tissue sur-
rounding the ablated lesion makes accurate assessment dif-
ficult, such evaluation does not immediately follow treat-
ment, however (Fig. 8). Whether ablation was successful is
usually determined on the basis of CT findings obtained at
least one month after the procedure. In our experience, re-
active hyperemia has usually resolved by this time. To de-
termine the possible presence of residual or recurrent tu-
mor, follow-up CT is scheduled every three months there-
after. 
Dynamic MRI with Gd-DTPA enhancement is also a
good method for evaluating therapeutic response. Areas of
the tumor in which treatment was successful do not
demonstrate the enhancement seen at contrast-enhanced
CT. 
Power Doppler ultrasonography (PDUS) using a mi-
crobubble contrast agent has recently been reported to be
a promising noninvasive technique for assessing the thera-
peutic response to RF ablation in HCC (34). Nonenhanced
PDUS was of little help in depicting residual intratumoral
flow signals, though contrast-enhanced PDUS was very
sensitive in the detection of residual tumor vascularity
within an ablated lesion (Fig. 9).
Results 
Several clinical series using different methods of RF ap-
plication for the treatment of HCC have been reported
(12, 13, 15 17, 20). Rossi et al. detailed their seven-year
experience with RF ablation in 50 patients with HCC or
hepatic metastases (15), reporting very promising survival
rates (for HCC patients) of 94%, 86%, 68%, and 40% at
1, 2, 3 and 5 years, respectively. Reported complete necro-
sis rates after RF ablation have varied according to the size
and morphology of the hepatic lesions. Livraghi et al. (16)
reported a complete necrosis rate of 90% in 42 patients
with 52 small HCCs (< 3 cm in diameter). This rate de-
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Fig. 7. Hepatic arterial-phase CT scan obtained one month after
RF ablation of a 4-cm HCC in the left hepatic lobe reveals the
presence of a round low-attenuating lesion (arrows). Note the fo-
cal contrast enhancement (arrowhead) in the posterior aspect of
the ablated lesion, indicative of viable untreated tumor. Additional
RF ablation was subsequently performed.
Fig. 8. Reactive hyperemia revealed by immediate post-treat-
ment CT.
Hepatic arterial-phase CT scan obtained 30 minutes after RF ab-
lation shows uniform rim-like contrast enhancement (arrows)
around the ablated lesion, a phenomenon frequently occurring
immediately after RF ablation and usually resolving prior to fol-
low-up CT at one month.Lim
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A
B
D
C
Fig. 9. HCC in a 67-year-old woman.
A. Hepatic arterial-phase CT scan shows an oval enhancing HCC (arrows), 4 cm in its greatest diameter, at the periphery of the right he-
patic lobe.
B. Unenhanced oblique power Doppler US scan obtained 18 hours after RF ablation shows a subtle flow signal (arrowhead) in the an-
tero-superior aspect of the ablated lesion.
C. Contrast-enhanced oblique power Doppler US scan obtained immediately after B, above, shows peripheral flow signals (arrows) with-
in the anterior aspect of the RF-ablated lesion, representing residual tumor. The residual flow signals seen on this contrast-enhanced
scan are better appreciated than on nonenhanced power Doppler US scan. 
D. Hepatic arterial-phase CT scan obtained 2 hours after RF ablation shows focal nodular contrast enhancement (arrowheads), indica-
tive of residual tumor, in the anterior aspect of the ablated lesion (arrows). The enhanced area corresponds to that in which residual flow
signals are present in the image described in C, above.creased, however, to 71% for medium HCCs (3.1 5.0 cm)
and to 25% for large ones (> 5.0 cm) (17). In an early ex-
perience with 51 HCCs (1.0 4.0 cm in diameter) at our in-
stitution, the complete necrosis rate was 94% (20). During
a recent one-year period, we used RF ablation alone for
the treatment of 108 patients with 125 nodular HCCs.
Fifty-seven of these 108, with 65 HCCs, underwent fol-
low-up helical CT not less than six months after the proce-
dure. Forty-five tumors were small (0.7 3.0 cm) and 20
were medium (3.1 5.0 cm). Six-month follow-up CT
showed complete necrosis of ablated tumor in 43 (96%) of
the 45 small lesions and in 18 (90%) of the 20 that were
medium-sized. After RF ablation, we found no major but
four minor complications (one small pneumothorax and
three cases of minor intraperitoneal bleeding) which disap-
peared spontaneously with no specific treatment (35).
Other investigators have also reported low complication
rates (12 17).
Summary and Conclusion 
On the basis of several clinical studies including ours, we
believe that RF ablation is a safe and highly effective tech-
nique for the local treatment of HCC, especially for small
tumors. RF ablation has several advantages over other ex-
isting therapies: it is minimally invasive, and for the treat-
ment of residual or recurrent tumors can be repeated.
Compared with PEI, RF ablation leads to a higher com-
plete necrosis rate and requires fewer treatment sessions
(16). 
The RF ablation of HCC may have its limitations. The
procedure is operator dependent, and for successful abla-
tion, accurate placement of the needle electrode is impera-
tive. In order to obtain good results, medical practicioners
should therefore be familiar with sonographically-guided
interventional techniques. The other limitation is that
abundant portal venous flow in normal liver tissue sur-
rounding the tumor may act as a heat sump, making com-
plete ablation of such tissue difficult. To decrease the effect
of portal venous flow, several experimental and clinical
studies are in progress. 
Although long-term follow-up evaluation of clinical out-
come is needed, RF ablation is safe and effective, and is
thus a highly promising technique for the local destruction
of HCC. Further improvements in the devices and tech-
niques employed may further increase its efficacy and safe-
ty.
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